Tumors with specific genetic mutations show response to immune checkpoint blockade therapy
New research shows that pathogenic polymerase epsilon and delta (POLE/POLD1) genetic mutations lead to improved response to immune checkpoint blockade, a powerful class of immunotherapy drugs. The findings contribute to a growing list of discoveries that prove certain classes of drugs are more effective in cases where the genetic makeup of the tumor — and not the type or origin of the tumor — should determine the decision-making process for treatment.
Materials provided by Cleveland Clinic. Note: Content may be edited for style and length.
Source link aaaaa